Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
about
Lumican expression in diaphragm induced by mechanical ventilationFeasibility of quantifying the mechanical properties of lung parenchyma in a small-animal model using (1)H magnetic resonance elastography (MRE).Amnion Epithelial Cells Promote Lung Repair via Lipoxin A4A novel single-chain-Fv antibody against connective tissue growth factor attenuates bleomycin-induced pulmonary fibrosis in mice.Innovative approaches to the therapy of fibrosisRac2 is involved in bleomycin-induced lung inflammation leading to pulmonary fibrosis.Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.Ultrasound assessment of ex vivo lung tissue properties using a fluid-filled negative pressure bathComprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation.Astaxanthin inhibits apoptosis in alveolar epithelial cells type II in vivo and in vitro through the ROS-dependent mitochondrial signalling pathway.3D MRI of impaired hyperpolarized 129Xe uptake in a rat model of pulmonary fibrosis.Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases.A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis.Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis.Prostaglandin Transporter (PGT/SLCO2A1) Protects the Lung from Bleomycin-Induced Fibrosis.Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis.Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice.Inhibition of α-SMA by the ectodomain of FGFR2c attenuates lung fibrosis.Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.Comparison between conventional and "clinical" assessment of experimental lung fibrosis.Update in diffuse parenchymal lung disease 2006.Serine/threonine kinase-protein kinase B and extracellular signal-regulated kinase regulate ventilator-induced pulmonary fibrosis after bleomycin-induced acute lung injury: a prospective, controlled animal experiment.The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis.Tissue turnover of collagen type I, III and elastin is elevated in the PCLS model of IPF and can be restored back to vehicle levels using a phosphodiesterase inhibitor.Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.Aortic carboxypeptidase-like protein is expressed in fibrotic human lung and its absence protects against bleomycin-induced lung fibrosis.Metformin Reduces Bleomycin-induced Pulmonary Fibrosis in Mice.Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats.Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice.Increased Cellular NAD+ Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice.Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in mice.Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway.Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta.Genetic susceptibility to interstitial pulmonary fibrosis in mice induced by vanadium pentoxide (V2O5).A mouse model of chronic idiopathic pulmonary fibrosis.Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics?New treatment and markers of prognosis for idiopathic pulmonary fibrosis: lessons learned from translational research.Translational models of lung disease.
P2860
Q28514000-5B2D370E-0E77-4D50-ADC1-1C9F07F1EED0Q30479754-F5E4448A-8D28-42DA-BB1B-4CBD0E6DB957Q33722569-76287DC8-8B8F-4D60-9ACB-844446938A30Q33803330-0B9BF556-7BEE-4CD8-9732-96E6341A64ACQ33824140-E990B755-E355-435C-940F-7FF9AC5644BAQ33849041-EF0C1DE7-E17F-4750-B2E4-31FA5A32F3A7Q33895012-37F7F16E-D80C-415A-BCAC-157CDE2EB678Q33902961-B4EAD7CF-6AFC-47BD-9EB4-0A2B20C1C970Q34160776-BC74733D-AE40-4E6F-A0F3-797428777764Q34473644-CF1C0846-FC8D-4CAC-A97C-92EB3523081AQ34498910-658878A6-F3CD-41CC-9334-857262F8D75AQ35161761-E6B9BA51-1231-4872-BC18-09EA30FF8DACQ35207651-FD744D15-5F1C-4200-B7BE-BA20C75456BFQ35325160-2592A75A-6E72-42F2-892B-1C7DA9C6703DQ35617407-8C9B073D-B4CE-4061-A9A5-89D33A0F8078Q35728036-AACCD045-D209-4325-AD28-44956AB22AF1Q35964652-A46AD8AC-599A-4F5E-9B12-46184CE0DC67Q36283405-3710711E-5C8B-493F-B484-9EC67B7E0AC9Q36613243-7255EDC7-A894-4D82-98C8-89F95344C8DBQ36628472-8155AA17-0C85-4C1B-8232-D1A59E4CB23CQ36769703-C2EE3B46-281A-4A08-8BB3-81E8C5FBE391Q36955268-1A2A7BB3-BD96-4103-8B73-15D71CE27101Q36970923-35563836-9467-4C18-85F1-5A062B40741FQ37042139-44559A23-B8A7-443A-B0BE-50B81815392BQ37089910-32049F49-4B3B-44DA-B531-031CFE953ABEQ37120665-C3DABF9F-F57F-445D-991B-12D7C99A19C9Q37150761-9481BACE-B430-4AFE-8CF4-C82714EA1154Q37153201-BF25A146-8A7D-4F69-979E-60270D366C3FQ37245959-3331E688-4C9C-4BAC-9F04-951115DB9556Q37266352-60174A4D-ABF6-4BF3-8F7D-4A7471FD1739Q37343785-15BCC74D-5E1B-4C88-A755-4034E1F8AC7AQ37362342-2CB23651-4401-4C3D-BEC7-9753D1254B82Q37376652-61561FAB-2114-4106-A184-5AFF1C09CBD8Q37421028-CF80C152-5C4B-4081-BCCC-6DA847FF1EBBQ37473340-CAC70B52-DD8C-4120-9800-05A727E89DD4Q37593998-EFB3F16F-21C3-44BA-8A4C-A981E0B88060Q37664164-1CA2B00E-3C74-4D01-9554-07BE64AE1A7CQ38019401-3C0F5440-716C-4BAC-9857-CBC04C790914Q38153815-37080F3A-1671-411F-A511-250E7C2D8D11Q38261287-4E03D2C2-CD69-47DC-BA13-E94572D1265D
P2860
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
@en
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
@nl
type
label
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
@en
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
@nl
prefLabel
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
@en
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
@nl
P2093
P1476
Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model.
@en
P2093
Andreas Schnapp
John E Park
Nveed I Chaudhary
P304
P356
10.1164/RCCM.200505-717OC
P407
P577
2006-01-13T00:00:00Z